GLP-1 Receptor Agonists (GLP-1 RAs) for Type 2 Diabetes and Obesity

1. Mechanism of Action: GLP-1 RAs (glucagon-like peptide-1 receptor agonists) and dual GIP/GLP-1 RAs work by:

• Enhancing glucose-stimulated insulin secretion from the pancreas.
• Suppressing inappropriate glucagon secretion, which helps reduce blood glucose levels.
• Slowing gastric emptying, promoting satiety, and reducing appetite, aiding in weight loss (1).

2. Approved Indications:

• Type 2 Diabetes Mellitus (T2DM): GLP-1 RAs and dual GIP/GLP-1 RAs are approved for T2DM management.
• Obesity: Some GLP-1 RAs (e.g., liraglutide, semaglutide, tirzepatide) are also approved for chronic weight management (2).

3. Benefits:

• Glycemic Control: Effective at lowering HbA1c, often comparable or superior to basal insulin (3,4).
• Weight Loss: Typically associated with weight reduction, unlike insulin, which may cause weight gain.
• Cardiovascular Benefits: Many GLP-1 RAs have shown reduced risk of major adverse cardiovascular events (5).
• Low Hypoglycemia Risk: Unlike insulin, GLP-1 RAs do not typically cause hypoglycemia when used as monotherapy (6).

4. Common Side Effects:

• Gastrointestinal issues (nausea, vomiting, diarrhea, constipation) are common, especially at initiation. These often improve over time (7).

5. Considerations for Use:

• Cost and Accessibility: GLP-1 RAs can be expensive, and availability may vary by region.
• Tolerability: Some patients may struggle with GI side effects, necessitating dose titration or alternative therapies (8).
• Combination Therapy: If already on GLP-1 RA or dual GIP/GLP-1 RA, continuing these is preferred over insulin for further glucose reduction due to lower hypoglycemia risk and weight benefits (9).

6. Dosing and Titration:

• Start at a low dose and titrate gradually to minimize side effects (e.g., semaglutide starts at 0.25 mg once weekly, increased as tolerated).
• If hypoglycemia occurs without clear cause, reduce the dose by 10-20% (10).

7. When to Consider Insulin Instead:

• If GLP-1 RAs are not tolerated, not effective, or not accessible, basal insulin (NPH or long-acting analogs) may be initiated (11).

8. Key Studies and Guidelines:

• GLP-1 RAs have shown superior efficacy and durability compared to insulin in some trials (123-130, 131).
• The 2024 ADA guidelines emphasize GLP-1 RAs as first-line injectable therapy for many patients with T2DM due to their comprehensive benefits (12).

Patient Guidance:

• Always take GLP-1 RAs as prescribed; do not skip doses. Report persistent nausea, vomiting, or severe GI symptoms to your doctor.
• Monitor blood glucose regularly and report hypoglycemia or unexpected side effects immediately.
• Discuss concerns about cost or insurance coverage with your healthcare provider or a pharmacist.